TrialHaemophilia : the official journal of the World Federation of Hemophilia2020

Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81-8973 from rFVIII-FS can continue their dosing schedule with improved protection.

Alexander Solms et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.